Medicine may change dramatically when a physician moves from the delivery room to the conference room, but the instinct to watch closely does not necessarily disappear. Dr. Roxana Ruta is one of those physicians. She began her medical career in the most fragile corner of medicine there is, the neonatal intensive care unit, and somehow carried that same vigilance, the instinct to notice the smallest change in a patient who cannot yet speak for themselves, into a career spent protecting the safety of patients in clinical trials around the world.
Today, she is the Executive Medical Director at Thermo Fisher Scientific, based in Bucharest, Romania, a post she stepped into in April 2026 and has now held for four months. It is the newest chapter of a career that has, without exaggeration, spanned nearly a quarter century.
First, the Nursery
Dr. Ruta trained as a medical doctor and specialized in Neonatology, and her earliest professional years read like a chronicle of newborn medicine in the city. From March 2002 to April 2007, five years and two months, she served as a Neonatology Resident at the Spitalul Universitar de Urgenta Bucuresti, the Emergency University Hospital, taking second-line on-call duty for neonatal emergencies, delivery room care, and intensive care unit work. Overlapping with that residency, from November 2003 to April 2007, three years and six months, she worked as a Neonatology Medical Doctor at Spitalul Clinic de Obstetrica si Ginecologie Filantropia, again handling first-line emergency coverage in the nursery and the neonatal intensive care unit.
From April 2007 to July 2010, three years and four months, she continued clinical on-call work in neonatology at Euroclinic Hospital in Bucharest, caring for both healthy newborns and critically ill infants. At Filantropia, she also served as a breastfeeding consultant at a hospital accredited by UNICEF as “Baby-friendly,” educating new mothers on the early care of their infants. It is a detail easy to overlook in a career built later on regulatory filings and safety oversight, but it says something about where her instincts as a physician originated.
The Pivot to Clinical Research
While still practicing neonatology, Dr. Ruta began building a second career in parallel. From May 2007 to May 2009, two years and one month, she worked as a Clinical Research Associate at AbCRO, coordinating clinical monitoring and site management in accordance with ICH GCP and FDA guidelines. She then moved to what would become the defining company of her career, joining what was then PPD in May 2009 as a Senior CRA, becoming a Senior CRA in November 2009, performing and coordinating clinical monitoring across sites in accordance with international regulatory standards.
She would go on to spend sixteen years and eleven months at PPD in total, an extraordinary run by any measure. From July 2010 to January 2019, eight years and seven months, she served as Associate Medical Director, working in a hybrid capacity out of Sofia. In that role, her principal therapeutic expertise centered on neonatology, pediatrics, rare diseases, and immunology, spanning Phase 1 through Phase 4 clinical trials and post-approval work, alongside a broader base of experience across other therapeutic areas. She served as global lead medical monitor for several rare disease programs, as well as vaccine and immunology and rheumatology pre-approval studies, and vaccine, CNS, and respiratory post-approval programs.
From January 2019 to March 2026, seven years and three months, she was promoted to Medical Director at PPD, based in Bucharest. Her responsibilities widened accordingly: providing medical oversight of clinical trials to protect subject safety and preserve the scientific integrity of the studies, reviewing clinical study reports and safety aggregate reports, contributing to medical affairs activities, advising on risk management, supporting clinical trial program development, and participating in business development.
Her therapeutic focus remained anchored in neonatology, pediatrics, rare diseases, and immunology, though her experience now extended to serving as medical monitor across several rare disease, infectious disease, cardiovascular, and obstetrics and gynecology preapproval studies.
Why the Safety Desk Matters
It is worth pausing here on what a Medical Director’s oversight actually protects. Behind every clinical study report and every safety aggregate report sits a set of real patients, often children, often people with diseases so rare that a single overlooked or misclassified adverse event could obscure a genuine safety signal. Dr. Ruta’s specific expertise in pharmacovigilance, birth defects evaluation, and the medical management of serious adverse event reports places her at exactly that intersection, the point where regulatory rigor and human consequence meet.
The Move to Thermo Fisher Scientific
In April 2026, after nearly seventeen years at PPD, Dr. Ruta joined Thermo Fisher Scientific as Executive Medical Director, again based in Bucharest. Her official biography describes a demonstrated history of working in the pharmaceuticals industry, a strong healthcare provider background skilled in pharmacovigilance, and continued responsibility for medical oversight of clinical trials to ensure compliance with ethics and regulatory requirements.
The role carries people management responsibilities alongside medical management of serious adverse event reports, and continues her long involvement in medical review of clinical study reports, safety aggregate reports, birth defects evaluation, and medical affairs activities, along with consultation on clinical trial program development and business development.
A Career Measured in Decades, Not Titles
What stands out most about Dr. Ruta’s record is its continuity. Across nearly a quarter century, from resident physician in a Bucharest delivery room to Executive Medical Director overseeing clinical programs involving global rare disease and immunology experience, the throughline never breaks. Every title change, from Sr. CRA to Associate Medical Director to Medical Director to Executive Medical Director, tracks an expanding circle of responsibility around the same core commitment: protecting the people, often the smallest and most vulnerable ones, at the center of a clinical trial.
Few Executive Medical Directors can point to hands-on neonatal intensive care experience as the foundation of their medical and clinical-trial oversight. For Dr. Ruta, that foundation is not incidental. It provides a direct clinical perspective for work that now requires her to assess safety, medical evidence, and the integrity of clinical studies across complex development programs.
She learned to watch over the smallest patients in a Bucharest nursery, and she has spent every year since bringing that same clinical vigilance to patients she may never meet.
